Literature DB >> 27069755

Clinical grade isolation of regulatory T cells from G-CSF mobilized peripheral blood improves with initial depletion of monocytes.

Pritesh Patel1, Dolores Mahmud2, Youngmin Park3, Kazumi Yoshinaga3, Nadim Mahmud4, Damiano Rondelli1.   

Abstract

Clinical isolation of circulating CD4(+)CD25(+) regulatory T cells (Tregs) from peripheral blood mononuclear cells is usually performed by CD4(+) cell negative selection followed by CD25(+) cell positive selection. Although G-CSF mobilized peripheral blood (G-PBSC) contains a high number of Tregs, a high number of monocytes in G-PBSC limits Treg isolation. Using a small scale device (MidiMACS, Miltenyi) we initially demonstrated that an initial depletion of monocytes would be necessary to obtaina separation of CD4(+)CD25(+)FoxP3(+)CD127(-) cells from G-PBSC (G-Tregs) with a consistent purity >70% and inhibitory activity of T cell alloreactivity in-vitro. We then validated the same approach in a clinical scale setting by separating G-Tregs with clinically available antibodies to perform a CD8(+)CD19(+)CD14(+) cell depletion followed by CD25(+) cell selection (2-step process) or by adding an initial CD14(+) cell depletion (3-step process) using a CliniMACS column. The 3-step approach resulted in a better purity (81±12% vs. 35±33%) and yield (66% vs. 39%). Clinically isolated G-Tregs were also FoxP3(+)CD127(dim) and functionally suppressive in-vitro. Our findings suggest that a better and more consistent purity of Tregs can be achieved from G-PBSC by an initial single depletion of monocytes prior to selection of CD4(+)CD25(+) cells.

Entities:  

Keywords:  CliniMACS; G-CSF; Regulatory T cells; stem cell transplantation

Year:  2015        PMID: 27069755      PMCID: PMC4769349     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  26 in total

1.  Efficient and reproducible large-scale isolation of human CD4+ CD25+ regulatory T cells with potent suppressor activity.

Authors:  David G Wichlan; Philippa L Roddam; Paul Eldridge; Rupert Handgretinger; Janice M Riberdy
Journal:  J Immunol Methods       Date:  2006-07-21       Impact factor: 2.303

2.  In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance.

Authors:  Dela Golshayan; Shuiping Jiang; Julia Tsang; Marina I Garin; Christian Mottet; Robert I Lechler
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

3.  Allogeneic T cells induce rapid CD34+ cell differentiation into CD11c+CD86+ cells with direct and indirect antigen-presenting function.

Authors:  Javaneh Abbasian; Dolores Mahmud; Nadim Mahmud; Sandeep Chunduri; Hiroto Araki; Pavan Reddy; Ronald Hoffman; Mario Arpinati; James L M Ferrara; Damiano Rondelli
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

4.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.

Authors:  Xingmin Feng; Sachiko Kajigaya; Elena E Solomou; Keyvan Keyvanfar; Xiuli Xu; Nalini Raghavachari; Peter J Munson; Thomas M Herndon; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

5.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

6.  Rapid induction of CD40 on a subset of granulocyte colony-stimulating factor-mobilized CD34(+) blood cells identifies myeloid committed progenitors and permits selection of nonimmunogenic CD40(-) progenitor cells.

Authors:  D Rondelli; R M Lemoli; M Ratta; M Fogli; F Re; A Curti; M Arpinati; S Tura
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

7.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

Authors:  Patricia A Taylor; Christopher J Lees; Bruce R Blazar
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

8.  Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes.

Authors:  Olivier Joffre; Thibault Santolaria; Denis Calise; Talal Al Saati; Denis Hudrisier; Paola Romagnoli; Joost P M van Meerwijk
Journal:  Nat Med       Date:  2007-12-09       Impact factor: 53.440

9.  T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells.

Authors:  D Rondelli; C Anasetti; A Fortuna; M Ratta; M Arpinati; G Bandini; R M Lemoli; S Tura
Journal:  Bone Marrow Transplant       Date:  1998-06       Impact factor: 5.483

Review 10.  Moving to tolerance: clinical application of T regulatory cells.

Authors:  Alicia N McMurchy; Andrew Bushell; Megan K Levings; Kathryn J Wood
Journal:  Semin Immunol       Date:  2011-05-28       Impact factor: 11.130

View more
  2 in total

Review 1.  Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?

Authors:  F Lussana; M Di Ianni; A Rambaldi
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

Review 2.  Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies.

Authors:  Richard Duggleby; Robert David Danby; J Alejandro Madrigal; Aurore Saudemont
Journal:  Front Immunol       Date:  2018-02-13       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.